Skip to main content

Aduro Biotech Value Stock - Dividend - Research Selection

Aduro Biotech

ISIN: US00739L1017, WKN: A14Q7F

Market price date: 30.11.-0001
Market price: 0,00 USD




Aduro Biotech Fundamental data and company key figures of the share

Annual reports in USD
Key figures 10-09-2020
Cash flow
Net operating cash flow -65.508.000
Capital Expenditures -1.260.000
Free cash flow -66.768.000
Balance sheet
Total Equity 65.595.000
Liabilities & Shareholders equity 291.313.000
Income statement
Net income -82.372.000
Eps (diluted) -5,150
Diluted shares outstanding 15.994.600
Net sales/revenue 17.258.000

Fundamental ratios calculated on: 30-11--0001

Ratios
Key figures 30-11--0001
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI0,00
ROE0,00
Income statement
P/E0,00
Div. Yield0,00%
P/B0,00
P/S0,00


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolADRO
Market Capitalization18.073.899.008,00 USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internetwww.aduro.com


Description of the company

Aduro Biotech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase II clinical trial in combination with pembrolizumab, an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and natural killer cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; and license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro Biotech, Inc. in June 2008. Aduro Biotech, Inc. was founded in 2000 and is headquartered in Berkeley, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.aduro.com